We are live on
!
Find out more
AbCellera Biologics
ABCL
ABCL
139 hedge funds and large institutions have $275M invested in AbCellera Biologics in 2024 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 52 increasing their positions, 34 reducing their positions, and 26 closing their positions.
New
Increased
Maintained
Reduced
Closed
53% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 34
3% less ownership
Funds ownership: 38.84% → 35.85% (-3%)
5% less funds holding
Funds holding: 146 → 139 (-7)
19% less capital invested
Capital invested by funds: $338M → $275M (-$63.2M)
27% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 26
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
51% less call options, than puts
Call options by funds: $407K | Put options by funds: $837K
Holders
139
Holders Change
-7
Holders Change %
-4.79%
% of All Funds
2%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.01%
New
19
Increased
52
Reduced
34
Closed
26
Calls
$407K
Puts
$837K
Net Calls
-$430K
Net Calls Change
-$357K
Top Buyers
| 1 |
PM
Prosight Management
Dallas,
Texas
|
+$18.6M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$5.09M |
| 3 |
Renaissance Technologies
New York
|
+$3.38M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$1.66M |
| 5 |
Two Sigma Investments
New York
|
+$1.31M |
